Unicycive Securities Fraud Class Action Over FDA CRL
Analysis based on 58 articles · First reported Sep 03, 2026 · Last updated Sep 22, 2026
The litigation and the underlying FDA Complete Response Letter have already driven a sharp decline in Unicycive's share price, and the pending class action adds legal and reputational overhang that could further pressure the stock and raise financing costs. Broader market impact is limited, as this is a single small-cap biotech issuer event with no systemic read-through beyond heightened scrutiny of FDA manufacturing-compliance disclosures in the sector.
Multiple investor-rights law firms have filed or announced securities fraud class action lawsuits against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its officers on behalf of investors who acquired Unicycive securities between December 29, 2025 and June 29, 2026. The complaints allege that Unicycive made materially false and misleading statements and failed to disclose that it had not inspected its third-party manufacturing vendor's facility or audited the facility's compliance with current good manufacturing practices; that it therefore lacked a reasonable basis to believe the vendor had remedied deficiencies cited by the United States — Food and Drug Administration; that there was an undisclosed risk the FDA would require additional information about the vendor's manufacturing practices; and that regulatory approval of oxylanthanum carbonate was reasonably likely to be delayed. According to the complaints, on June 30, 2026, before market open, Unicycive disclosed that the FDA had issued a Complete Response Letter regarding its resubmitted New Drug Application for OLC, identifying the same third-party manufacturing deficiencies cited in a prior June 2025 CRL. On that news, Unicycive's stock reportedly fell $3.01, or 39.1%, to close at $4.69 per share on June 30, 2026. Bronstein, Gewirtz & Grossman, LLC, Glancy Prongay & Murray, The Law Offices of Frank R. Cruz, and the Law Offices of Howard G. Smith have each publicized the action and are soliciting investors. Investors have until November 2, 2026 to seek appointment as lead plaintiff.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard